Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Active not recruiting 4Terminated 2Completed 2Unknown 1Recruiting 1

Sponsor Class

OTHER 3NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Sarcoma 4Dermatologic 2Lymphoid 1

Conditions

Sarcoma 4Neoplasm Metastasis 1Liposarcoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1

Interventions

Cyclophosphamide 22Specimen Handling 20Magnetic Resonance Spectroscopy 20pembrolizumab 18Nivolumab 18Radiotherapy 17Biopsy 16Doxorubicin 15Temozolomide 14Radiation 14X-Rays 9Irinotecan 9Ipilimumab 9Ifosfamide 9fludarabine 8Phantoms, Imaging 8Etoposide 8cabozantinib 7Vincristine 7Carboplatin 7Bevacizumab 7regorafenib 6Sirolimus 6palbociclib 5olaparib 5fludarabine phosphate 5durvalumab 5Vinorelbine 5Sunitinib 5Radiosurgery 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Active not recruiting × talimogene laherparepvec × Sarcoma × Clear all
NCT02923778 2026-05-13

Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Active not recruiting
40 enrolled
Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma, Histiocytoma, Malignant Fibrous

NCT04599062 2026-01-29

TVEC and Preop Radiation for Sarcoma (8 ml Dose)

University of Iowa

Phase 1/2 Active not recruiting
8 enrolled 8 charts
Sarcoma

Sarcoma

NCT06660810 2026-01-15

Neoadjuvant Intralesional Injection of Talimogene Laherparepvec

University of Iowa

Phase 2 Active not recruiting
2 enrolled
Sarcoma

Sarcoma

NCT03069378 2025-10-29

A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
41 enrolled 8 charts
Sarcoma

Neoplasm Metastasis, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡